261 related articles for article (PubMed ID: 31412266)
1. Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?
Kokkinos A; Tsilingiris D; le Roux CW; Rubino F; Mantzoros CS
Metabolism; 2019 Nov; 100():153960. PubMed ID: 31412266
[TBL] [Abstract][Full Text] [Related]
2. Treating obesity: is it all in the gut?
Davenport RJ; Wright S
Drug Discov Today; 2014 Jul; 19(7):845-58. PubMed ID: 24291217
[TBL] [Abstract][Full Text] [Related]
3. Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery.
Martinou E; Stefanova I; Iosif E; Angelidi AM
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328759
[TBL] [Abstract][Full Text] [Related]
4. Gut hormones as therapeutic agents in treatment of diabetes and obesity.
Tan T; Bloom S
Curr Opin Pharmacol; 2013 Dec; 13(6):996-1001. PubMed ID: 24060699
[TBL] [Abstract][Full Text] [Related]
5. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus.
Vetter ML; Cardillo S; Rickels MR; Iqbal N
Ann Intern Med; 2009 Jan; 150(2):94-103. PubMed ID: 19153412
[TBL] [Abstract][Full Text] [Related]
6. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
7. The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity.
Koliaki C; Liatis S; Dalamaga M; Kokkinos A
Curr Obes Rep; 2020 Sep; 9(3):255-271. PubMed ID: 32647952
[TBL] [Abstract][Full Text] [Related]
8. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.
Grams J; Garvey WT
Curr Obes Rep; 2015 Jun; 4(2):287-302. PubMed ID: 26627223
[TBL] [Abstract][Full Text] [Related]
9. Gut Peptide Agonism in the Treatment of Obesity and Diabetes.
Grandl G; Novikoff A; DiMarchi R; Tschöp MH; Müller TD
Compr Physiol; 2019 Dec; 10(1):99-124. PubMed ID: 31853954
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years.
Rose F; Bloom S; Tan T
Expert Opin Drug Discov; 2019 Nov; 14(11):1151-1159. PubMed ID: 31355685
[No Abstract] [Full Text] [Related]
11. Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones.
Behary P; Cegla J; Tan TM; Bloom SR
Postgrad Med; 2015 Jun; 127(5):494-502. PubMed ID: 26040552
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in the treatment of 'diabesity': beyond GLP-1.
Tharakan G; Tan T; Bloom S
Trends Pharmacol Sci; 2011 Jan; 32(1):8-15. PubMed ID: 21130506
[TBL] [Abstract][Full Text] [Related]
13. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery.
Holst JJ
Curr Opin Pharmacol; 2013 Dec; 13(6):983-8. PubMed ID: 24161809
[TBL] [Abstract][Full Text] [Related]
14. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones.
Meek CL; Lewis HB; Reimann F; Gribble FM; Park AJ
Peptides; 2016 Mar; 77():28-37. PubMed ID: 26344355
[TBL] [Abstract][Full Text] [Related]
15. Future therapies for obesity.
Melson E; Miras AD; Papamargaritis D
Clin Med (Lond); 2023 Jul; 23(4):337-346. PubMed ID: 37524416
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal Hormones, Intestinal Microbiota and Metabolic Homeostasis in Obese Patients: Effect of Bariatric Surgery.
Federico A; Dallio M; Tolone S; Gravina AG; Patrone V; Romano M; Tuccillo C; Mozzillo AL; Amoroso V; Misso G; Morelli L; Docimo L; Loguercio C
In Vivo; 2016; 30(3):321-30. PubMed ID: 27107092
[TBL] [Abstract][Full Text] [Related]
17. Metabolic surgery and gut hormones - a review of bariatric entero-humoral modulation.
Ashrafian H; le Roux CW
Physiol Behav; 2009 Jul; 97(5):620-31. PubMed ID: 19303889
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal hormones and bariatric surgery-induced weight loss.
Ionut V; Burch M; Youdim A; Bergman RN
Obesity (Silver Spring); 2013 Jun; 21(6):1093-103. PubMed ID: 23512841
[TBL] [Abstract][Full Text] [Related]
19. GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice.
van Witteloostuijn SB; Dalbøge LS; Hansen G; Midtgaard SR; Jensen GV; Jensen KJ; Vrang N; Jelsing J; Pedersen SL
J Pept Sci; 2017 Dec; 23(12):845-854. PubMed ID: 29057588
[TBL] [Abstract][Full Text] [Related]
20. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Baretić M; Troskot R
Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
